

Belzutifan (WELIREG) Criteria for Use in Von Hippel-Lindau (VHL) Disease February 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive belzutifan.

- Immediate need for surgical intervention for tumor treatment
- No evidence of metastatic disease
- Pregnancy
- Lactation

Inclusion Criteria

The following criteria must be met:

- Von Hippel-Lindau (VHL) Disease, based on germline VHL alteration, and associated renal cell carcinoma, central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocrine tumor not requiring surgery

Additional Inclusion Criteria

All of the following criteria must be met:

- Care is provided by a VA/VA Community Care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented

Additional Inclusion Criteria (If applicable)

- For females who can become pregnant and male patients with female partners who can become pregnant: Counseling provided on potential risks vs benefits and the use of effective contraception during therapy and for 1 week after stopping treatment

Other Justification

Prepared: January 2025. Contact: Mark C. Geraci, Pharm.D., BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)
